Using Volumetric Flow to Scaleup Chromatographic Processes - - BioPharm International


Using Volumetric Flow to Scaleup Chromatographic Processes

BioPharm International
Volume 19, Issue 3

However, Figure 1 also shows another important aspect: Scaling down (reducing column length) will result in worse or unchanged separation because N is reduced. As a consequence it is important during process development to find and operate the shortest possible column suitable for the separation. This has two benefits: reduced demand for test material during development and a safely up-scalable process.

To summarize the rules of obtaining flexibility during scaleup:

  • Maintain constant flowrate Q in CV/h (not v in cm/h)
  • Minimize bed height for successful separation
  • Maximize bed height while keeping pressure drop reasonable.

Since the cycle time is constant (constant CV/h) the productivity [g/Lgel/h] is constant, therefore the capacity [g/h] can be adjusted by changing the bed height.

Figure 2. Example of scale up on a volume basis from lab to pilot and in pilot (different bed heights and diameters). Q = 12 CV/h.


An example of scaling up on a volume basis directly from lab-scale to pilot-scale (by a factor 274) is shown in Figure 2. For all experiments we use columns 20 to 35 cm long. The 20-cm column length was measured as 610 plates at Q = 11 CV/h. As both experiments showed identical elution and impurity profiles we have obtained the same separation and thus successfully scaled the process. However, the transfer from lab to pilot resulted in a significant larger retention volume. This deviation arises from extra column effects.

Figure 3. Areas equal the dead volumes of different systems, 0.16 CV for the lab and 1.07 CV for pilot. c/c0 is the scaled concentration

The deviation of 2.3 CV was initially attributed to a difference in the dead volumes. These were calculated by numerical integration as the area between the nominal gradient (programmed gradient) and the lab or the pilot gradient (Figure 3) and found to be 0.16 CV and 1.07 CV respectively. This difference of 0.91 CV, obviously did not account for the deviation.

Figure 4. The pilot response curve shows that the delay volume (2.6 CV) is made up by two contributions, one from tubing (0.7 CV) and one from mixer (1.9 CV).

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here